Literature DB >> 33282185

Role of biomarkers in evaluation, treatment and clinical studies of pulmonary arterial hypertension.

Anna Hemnes1, Alexander M K Rothman2, Andrew J Swift2, Lawrence S Zisman3.   

Abstract

Pulmonary arterial hypertension is a complex disease resulting from the interplay of myriad biological and environmental processes that lead to remodeling of the pulmonary vasculature with consequent pulmonary hypertension. Despite currently available therapies, there remains significant morbidity and mortality in this disease. There is great interest in identifying and applying biomarkers to help diagnose patients with pulmonary arterial hypertension, inform prognosis, guide therapy, and serve as surrogate endpoints. An extensive literature on potential biomarker candidates is available, but barriers to the implementation of biomarkers for clinical use in pulmonary arterial hypertension are substantial. Various omic strategies have been undertaken to identify key pathways regulated in pulmonary arterial hypertension that could serve as biomarkers including genomic, transcriptomic, proteomic, and metabolomic approaches. Other biologically relevant components such as circulating cells, microRNAs, exosomes, and cell-free DNA have recently been gaining attention. Because of the size of the datasets generated by these omic approaches and their complexity, artificial intelligence methods are being increasingly applied to decipher their meaning. There is growing interest in imaging the lung with various modalities to understand and visualize processes in the lung that lead to pulmonary vascular remodeling including high resolution computed tomography, Xenon magnetic resonance imaging, and positron emission tomography. Such imaging modalities have the potential to demonstrate disease modification resulting from therapeutic interventions. Because right ventricular function is a major determinant of prognosis, imaging of the right ventricle with echocardiography or cardiac magnetic resonance imaging plays an important role in the evaluation of patients and may also be useful in clinical studies of pulmonary arterial hypertension.
© The Author(s) 2020.

Entities:  

Keywords:  biomarker; genomics–metabolomics–proteomics; imaging; pharmacogenomics; pulmonary arterial hypertension

Year:  2020        PMID: 33282185      PMCID: PMC7682212          DOI: 10.1177/2045894020957234

Source DB:  PubMed          Journal:  Pulm Circ        ISSN: 2045-8932            Impact factor:   2.886


  118 in total

1.  miR-4632 mediates PDGF-BB-induced proliferation and antiapoptosis of human pulmonary artery smooth muscle cells via targeting cJUN.

Authors:  Zhengjiang Qian; Yanjiao Li; Jidong Chen; Xiang Li; Deming Gou
Journal:  Am J Physiol Cell Physiol       Date:  2017-07-12       Impact factor: 4.249

2.  Diagnostic and prognostic value of right ventricular strain in patients with pulmonary arterial hypertension and relatively preserved functional capacity studied with echocardiography and magnetic resonance.

Authors:  Augusto Alberto da Costa Junior; Jaquelina Sonoe Ota-Arakaki; Roberta Pulcheri Ramos; Marly Uellendahl; Frederico José Neves Mancuso; Manuel Adan Gil; Cláudio Henrique Fischer; Valdir Ambrosio Moises; Antonio Carlos de Camargo Carvalho; Orlando Campos
Journal:  Int J Cardiovasc Imaging       Date:  2016-08-26       Impact factor: 2.357

3.  Quantification of the Pulmonary Vascular Response to Inhaled Nitric Oxide Using Noncontrast Computed Tomography Imaging.

Authors:  Farbod Nicholas Rahaghi; Tilo Winkler; Puja Kohli; Pietro Nardelli; Berta Martí-Fuster; James C Ross; Ramya Radhakrishnan; Tyler Blackwater; Samuel Y Ash; Isaac de La Bruere; Alejandro A Diaz; Richard N Channick; R Scott Harris; George R Washko; Raúl San José Estépar
Journal:  Circ Cardiovasc Imaging       Date:  2019-12       Impact factor: 7.792

4.  Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Alan L Hinderliter; Adam Torbicki; Thierry Fourme; Gerald Simonneau; Tomas Pulido; Nilda Espinola-Zavaleta; Guido Rocchi; Alessandra Manes; Robert Frantz; Marcin Kurzyna; Sherif F Nagueh; Robyn Barst; Richard Channick; Karl Dujardin; Andrew Kronenberg; Isabelle Leconte; Maurizio Rainisio; Lewis Rubin
Journal:  J Am Coll Cardiol       Date:  2003-04-16       Impact factor: 24.094

Review 5.  Mitochondrial metabolism in pulmonary hypertension: beyond mountains there are mountains.

Authors:  Miranda K Culley; Stephen Y Chan
Journal:  J Clin Invest       Date:  2018-08-06       Impact factor: 14.808

6.  Exome Sequencing in Children With Pulmonary Arterial Hypertension Demonstrates Differences Compared With Adults.

Authors:  Na Zhu; Claudia Gonzaga-Jauregui; Carrie L Welch; Lijiang Ma; Hongjian Qi; Alejandra K King; Usha Krishnan; Erika B Rosenzweig; D Dunbar Ivy; Eric D Austin; Rizwan Hamid; William C Nichols; Michael W Pauciulo; Katie A Lutz; Ashley Sawle; Jeffrey G Reid; John D Overton; Aris Baras; Frederick Dewey; Yufeng Shen; Wendy K Chung
Journal:  Circ Genom Precis Med       Date:  2018-04

7.  A Potential Role for Exosomal Translationally Controlled Tumor Protein Export in Vascular Remodeling in Pulmonary Arterial Hypertension.

Authors:  Elisabet Ferrer; Benjamin J Dunmore; Dhiya Hassan; Mark L Ormiston; Stephen Moore; John Deighton; Lu Long; Xu Dong Yang; Duncan J Stewart; Nicholas W Morrell
Journal:  Am J Respir Cell Mol Biol       Date:  2018-10       Impact factor: 6.914

8.  SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Pavel Jansa; Tomás Pulido; Richard N Channick; Marion Delcroix; Hossein-Ardeschir Ghofrani; Franck-Olivier Le Brun; Sanjay Mehta; Loïc Perchenet; Lewis J Rubin; B K S Sastry; Gérald Simonneau; Olivier Sitbon; Rogério Souza; Adam Torbicki
Journal:  Eur Heart J       Date:  2017-04-14       Impact factor: 29.983

9.  Identifying "super responders" in pulmonary arterial hypertension.

Authors:  Stephen J Halliday; Anna R Hemnes
Journal:  Pulm Circ       Date:  2017-05-30       Impact factor: 3.017

10.  Machine Learning of Three-dimensional Right Ventricular Motion Enables Outcome Prediction in Pulmonary Hypertension: A Cardiac MR Imaging Study.

Authors:  Timothy J W Dawes; Antonio de Marvao; Wenzhe Shi; Tristan Fletcher; Geoffrey M J Watson; John Wharton; Christopher J Rhodes; Luke S G E Howard; J Simon R Gibbs; Daniel Rueckert; Stuart A Cook; Martin R Wilkins; Declan P O'Regan
Journal:  Radiology       Date:  2017-01-16       Impact factor: 11.105

View more
  4 in total

Review 1.  Severe Aortic Valve Stenosis and Pulmonary Hypertension: A Systematic Review of Non-Invasive Ways of Risk Stratification, Especially in Patients Undergoing Transcatheter Aortic Valve Replacement.

Authors:  Elke Boxhammer; Alexander E Berezin; Vera Paar; Nina Bacher; Albert Topf; Sergii Pavlov; Uta C Hoppe; Michael Lichtenauer
Journal:  J Pers Med       Date:  2022-04-08

Review 2.  Exploring Functional Differences between the Right and Left Ventricles to Better Understand Right Ventricular Dysfunction.

Authors:  Judith Bernal-Ramirez; Magda C Díaz-Vesga; Matias Talamilla; Andrea Méndez; Clara Quiroga; Javier A Garza-Cervantes; Anay Lázaro-Alfaro; Carlos Jerjes-Sanchez; Mauricio Henríquez; Gerardo García-Rivas; Zully Pedrozo
Journal:  Oxid Med Cell Longev       Date:  2021-08-28       Impact factor: 6.543

3.  Veno-Arterial Extracorporeal Membrane Oxygenation Rescue in a Patient With Pulmonary Hypertension Presenting for Revision Total Hip Arthroplasty: A Case Report and Narrative Review.

Authors:  Ailan Zhang; Virgilio De Gala; Peter W Lementowski; Draginja Cvetkovic; Jeff L Xu; Andrew Villion
Journal:  Cureus       Date:  2022-08-21

4.  Resveratrol Prevents Right Ventricle Dysfunction, Calcium Mishandling, and Energetic Failure via SIRT3 Stimulation in Pulmonary Arterial Hypertension.

Authors:  Judith Bernal-Ramírez; Christian Silva-Platas; Carlos Jerjes-Sánchez; Martín R Ramos-González; Eduardo Vázquez-Garza; Héctor Chapoy-Villanueva; Alicia Ramírez-Rivera; Ángel Zarain-Herzberg; Noemi García; Gerardo García-Rivas
Journal:  Oxid Med Cell Longev       Date:  2021-06-20       Impact factor: 6.543

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.